The global landscape for treating liquid tumors is undergoing a seismic shift as genomic profiling becomes the gold standard in clinical practice. In 2026, the industry has moved decisively away from broad-spectrum chemotherapy toward precision medicine that targets specific genetic mutations. This transition is not only improving patient survival rates but also reshaping how pharmaceutical...